Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRI NASDAQ:ITRM NASDAQ:RENB NASDAQ:RNTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$0.84+1.0%$0.91$0.54▼$2.22$8.45M0.49365,933 shs34,794 shsITRMIterum Therapeutics$0.68-3.7%$0.79$0.61▼$3.02$33.44M3.04687,689 shs1.24 million shsRENBRenovaro$0.20-0.9%$0.26$0.18▼$2.10$34.53M0.54867,251 shs591,042 shsRNTXRein Therapeutics$1.19+10.2%$1.28$1.04▼$4.40$27.73M1.13125,259 shs41,191 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera0.00%-0.37%-12.92%+27.65%-36.27%ITRMIterum Therapeutics0.00%+0.63%-16.77%-31.12%-35.31%RENBRenovaro0.00%-3.78%-16.51%-45.61%-69.54%RNTXRein Therapeutics0.00%-10.53%+3.03%-36.70%+118,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$0.84+1.0%$0.91$0.54▼$2.22$8.45M0.49365,933 shs34,794 shsITRMIterum Therapeutics$0.68-3.7%$0.79$0.61▼$3.02$33.44M3.04687,689 shs1.24 million shsRENBRenovaro$0.20-0.9%$0.26$0.18▼$2.10$34.53M0.54867,251 shs591,042 shsRNTXRein Therapeutics$1.19+10.2%$1.28$1.04▼$4.40$27.73M1.13125,259 shs41,191 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera0.00%-0.37%-12.92%+27.65%-36.27%ITRMIterum Therapeutics0.00%+0.63%-16.77%-31.12%-35.31%RENBRenovaro0.00%-3.78%-16.51%-45.61%-69.54%RNTXRein Therapeutics0.00%-10.53%+3.03%-36.70%+118,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera 3.00Buy$2.75226.91% UpsideITRMIterum Therapeutics 3.00Buy$9.001,218.68% UpsideRENBRenovaro 0.00N/AN/AN/ARNTXRein Therapeutics 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest BFRI, RENB, RNTX, and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025RNTXRein TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$37.32M0.23N/AN/A$0.57 per share1.48ITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/ARENBRenovaroN/AN/AN/AN/A$0.89 per shareN/ARNTXRein TherapeuticsN/AN/A$0.49 per share2.41$0.43 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$17.76M-$2.26N/AN/AN/A-42.34%-1,104.09%-82.28%11/12/2025 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.85N/A∞N/AN/AN/A-65.01%11/13/2025 (Estimated)RENBRenovaro-$88.43M-$0.77N/A∞N/AN/A-60.38%-47.04%9/29/2025 (Estimated)RNTXRein Therapeutics-$62.88M-$2.69N/AN/AN/AN/A-141.11%-33.83%N/ALatest BFRI, RENB, RNTX, and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RNTXRein Therapeutics-$0.22-$0.28-$0.06-$0.28N/AN/A8/13/2025Q2 2025BFRIBiofrontera-$0.45-$0.57-$0.12-$0.57$8.30 million$9.03 million8/5/2025Q2 2025ITRMIterum Therapeutics-$0.13-$0.16-$0.03-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ARENBRenovaroN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofrontera8.990.960.75ITRMIterum TherapeuticsN/A2.692.52RENBRenovaroN/A0.130.13RNTXRein TherapeuticsN/A0.860.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%ITRMIterum Therapeutics9.21%RENBRenovaro71.41%RNTXRein Therapeutics90.89%Insider OwnershipCompanyInsider OwnershipBFRIBiofrontera4.80%ITRMIterum Therapeutics2.40%RENBRenovaro0.50%RNTXRein Therapeutics5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera7010.14 million9.65 millionNo DataITRMIterum Therapeutics1047.17 million46.04 millionNot OptionableRENBRenovaro20172.12 million171.26 millionOptionableRNTXRein Therapeutics923.31 million22.12 millionN/ABFRI, RENB, RNTX, and ITRM HeadlinesRecent News About These CompaniesRein Therapeutics (NASDAQ:RNTX) Shares Down 9.2% - What's Next?September 12 at 4:15 AM | americanbankingnews.comRein Therapeutics files to sell 10M shares of common stock for holdersSeptember 3, 2025 | msn.comBrookline Capital Downgrades Rein Therapeutics (RNTX)August 19, 2025 | msn.comRein announces U.K. MHRA authorized to initiate Phase 2 ‘RENEW’ trialAugust 19, 2025 | msn.comRein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary FibrosisAugust 19, 2025 | globenewswire.comRein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025August 14, 2025 | globenewswire.comXtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery CollaborationAugust 7, 2025 | finance.yahoo.comRein Therapeutics Enters into Agreements for up to $21 Million in Flexible FinancingJuly 30, 2025 | finance.yahoo.comRNTX - Rein Therapeutics Inc Dividends - MorningstarJune 26, 2025 | morningstar.comMRein Therapeutics Announces Adjournment of Annual Meeting of StockholdersJune 24, 2025 | prnewswire.comUS FDA puts on hold Rein Therapeutics' lung disease drug trialJune 12, 2025 | reuters.comRNTX Rein Therapeutics Inc.June 1, 2025 | seekingalpha.comRein Therapeutics, Inc.: Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 27, 2025 | finanznachrichten.deRein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 27, 2025 | prnewswire.comRein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International ConferenceMay 19, 2025 | prnewswire.comRein Therapeutics, Inc.: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 16, 2025 | finanznachrichten.deRein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | prnewswire.comRein Therapeutics begins trial for idiopathic pulmonary fibrosis treatmentMay 13, 2025 | msn.comRein Therapeutics, Inc.: Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 12, 2025 | finanznachrichten.deRein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 12, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBFRI, RENB, RNTX, and ITRM Company DescriptionsBiofrontera NASDAQ:BFRI$0.84 +0.01 (+0.98%) Closing price 09/12/2025 03:47 PM EasternExtended Trading$0.84 0.00 (-0.50%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Iterum Therapeutics NASDAQ:ITRM$0.68 -0.03 (-3.72%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$0.68 0.00 (-0.37%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Renovaro NASDAQ:RENB$0.20 0.00 (-0.95%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.21 +0.01 (+4.18%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.Rein Therapeutics NASDAQ:RNTX$1.19 +0.11 (+10.19%) As of 09/12/2025 03:59 PM EasternRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
